1. Introduction {#s0005}
===============

Orofacial clefts are among the commonest birth defects with a worldwide frequency of 1 in 750 live births. About 70% of clefts are non-syndromic that occur in isolated conditions while the remaining 30% are syndromic clefts that are associated with other cognitive or structural anomalies. Based on different clinical manifestations, non-syndromic cleft lip and palate (NSCL/P) is categorized into two groups - cleft lip with or without cleft palate (CL/P) and cleft palate only (CPO) ([@bb0090]). CPO is less common than CL/P. The incidence of non-syndromic clefts shows variations depending upon economic, geographical and genetic backgrounds. Asians and Native Americans exhibited the highest prevalence rates, followed by Caucasians and Africans ([@bb0095]).

Over the last decade, numerous linkage and association studies have been performed to identify the genes that predispose to NSCL/P. The development of lip and palate is known to be dependent on a spectrum of signaling molecules, transcription factors and growth factors. However, the relative contribution of individual susceptibility genes varies across different populations, thereby accentuating the need for replication of association studies in different populations. Transcription factors are DNA-binding proteins capable of activating or repressing gene regulation. The transcription factor AP-2 alpha, encoded by the *TFAP2A* gene, is another important functional candidate for the non-syndromic oral clefts. The gene coding for AP-2 alpha transcription factor (*TFAP2A*) is located on 6p24-p22.3 and composed of seven exons with the last six exons encoding the majority of the protein. AP-2 alpha protein acts as a sequence specific DNA-binding transcription factor, recognizing and binding to the specific GC-rich regions that are present in the cis-regulatory regions of several cellular genes. Thus it regulates gene expression during the embryogenesis of eye, ear, face, body wall and limbs ([@bb0005]).

The first evidence to prove that *TFAP2A* gene is a risk factor for cleft lip/palate is derived from the breakpoints within 375 to 930 kb of the 5′-end of the *TFAP2A* gene in 3 patients that showed balanced translocations \[46,XX,t(6;9)(p23;q22.3)\] involving 6p ([@bb0045], [@bb0050]). Several genome-wide linkage scans have provided evidence for linkage between 6p23 region that harbor *TFAP2A* gene and NSCL/P in different populations ([@bb0030], [@bb0105], [@bb0085], [@bb0115]). The *TFAP2A* has been identified as a causative gene for Branchio-Oculo-Facial Syndrome (BOFS) that commonly presents with facial clefting ([@bb0065]). The present study aims to investigate the role of *TFAP2A* gene polymorphisms in the pathogenesis of NSCL/P in south Indian population.

2. Materials & methods {#s0010}
======================

2.1. Subjects {#s0015}
-------------

The study included a total of 349 individuals of both sexes, consisting of 176 NSCL/P cases and 173 controls. All the subjects were recruited at Sri Ramachandra Cleft and Craniofacial Centre, Sri Ramachandra University, Chennai, India. The case groups were examined by two surgeons to assess the exact cleft phenotype. Cases with possible specific malformations and those with intellectual disability or other anomalies were excluded from the study. Subjects without family history of clefting were recruited as controls. The study was approved by Institution Ethics Committee of Sri Ramachandra University (Ref:IEC-NI/II/OCT/25/60 dated 12.01.2012) and informed consent was obtained from all the participants. Consent was collected from parent or legal guardian when the subject was a minor.

2.2. Genotyping {#s0020}
---------------

3 ml peripheral blood samples were collected from all the subjects. DNA was isolated from the leukocytes using a standard procedure. Three SNPs reported in a previous study ([@bb0120]), \[rs1675414 (Exon 1), rs3798691 (Intron 1), and rs303050 (Intron 4)\] were selected for analysis. Genotyping was performed using KASPar chemistry (KBioscience Ltd., Hoddesdon, UK), which is a competitive allele-specific PCR-SNP genotyping system that uses FRET quencher cassette oligos ([@bb0055], [@bb0040]). On the basis of the fluorescence obtained, the allele call data were viewed graphically as a scatter plot for each marker assayed using the SNPViewer (<http://www.lgcgenomics.com>).

2.3. Statistical analysis {#s0025}
-------------------------

Hardy-Weinberg equilibrium (HWE) was assessed for all polymorphisms in both cases and controls groups by using chi-square test. Allele frequencies were estimated by the gene counting method ([@bb0035]). Comparison of genotype and allele frequencies among cases and the control groups were analyzed by the chi-square test. Odds ratio (OR) and 95% confidence intervals (CI) were calculated using wild type genotypes or allele as reference group. Pairwise linkage disequilibrium (LD) was computed as both of D′ and r^2^ for *TFAP2A* gene by using of the Haploview ([@bb0010]) Genotype-genotype interaction was calculated by using Multifactor Dimensionality Reduction (MDR) 3.0.2 software ([@bb0060]).

3. Results {#s0030}
==========

The genotype frequencies of three *TFAP2A* variants were distributed according to the Hardy-Weinberg equilibrium among the controls. There were no significant differences in genotypic distribution between cases and controls of the three variants ([Table 1](#t0005){ref-type="table"}). Odds ratio analysis showed that the variant rs3798691 was associated with decreasing risk trend of oral clefts while the other two variants, namely rs1675414 and rs303050 were associated with an increased risk of oral clefts. However, none of the models mentioned above reached statistical significance ([Table 1](#t0005){ref-type="table"}). Genotype and allele frequency distribution of *TFAP2A* variants by cleft phenotype was depicted in [Fig. S1](#f0015){ref-type="graphic"}. In subgroup analysis by cleft phenotype, no significant associations were found for all *TFAP2A* polymorphisms ([Supplementary Table S1](#ec0005){ref-type="supplementary-material"}). Measures of pairwise LD presented in [Fig. 1](#f0005){ref-type="fig"} revealed that the *TFAP2A* polymorphisms were in LD as evidenced by lower r^2^ values. Haplotype analysis was not informative.

Multi-dimensional reductionality scaling approach was employed to evaluate the epistasis and to characterize the potential interactions of *TFAP2A* gene polymorphisms on NSCL/P risk ([Table 2](#t0010){ref-type="table"}). The best model predicted for 1, 2 and 3 locus interactions were not significant. Both two locus (rs1675414 and rs303050) and three locus (rs1675414, rs3798691 and rs303050) interaction models were selected 10 out of 10 times by MDR based on a cross-validation consistency (CVC) score of 100% and predictive accuracy of 52.8% ([Table 2](#t0010){ref-type="table"}). Furthermore, we observed a lesser mutual information for the combined effect of any two polymorphisms, in contrast to rs303050 alone (I = 0.84%) or rs1675414 alone (I = 0.50%), as depicted in entropy-based interaction dendrograms ([Fig. 2](#f0010){ref-type="fig"}).

4. Discussion {#s0035}
=============

Analysis of three SNPs within the *TFAP2A* gene did not show any significant association with NSCL/P. No significant linkage disequilibrium was detected between markers. MDR analysis did not show a significant effect of the *TFAP2A* gene polymorphisms on susceptibility to NSCL/P. Similar findings were also observed in the Northern Chinese population ([@bb0120]). In contrast to the above mentioned results, both single marker and haplotypes were associated with NSCL/P in a family based association analysis of Italian NSCL/P triads ([@bb0070]). Earlier studies observed that loss of AP-2 alpha caused severe craniofacial, limb and skin defects ([@bb0110], [@bb0130]). Further, AP-2 alpha-null chimeras exhibit midline craniofacial clefting, acrania, and a failure of sternal fusion ([@bb0100]). Furthermore, tissue specific deletion of AP-2 alpha gene revealed that palatal development is independent of neural tube closure, but neural crest-specific expression of AP-2 alpha is essential for particular aspects of craniofacial development ([@bb0025]). Numerous patients with Branchio-Oculo-Facial Syndrome have mutations in the DNA binding domain of *TFAP2A*, suggesting importance of downstream transcriptional targets ([@bb0125], [@bb0080]). While some previous studies demonstrated the binding of *TFAP2A* to the IRF6 enhancer (MCS-9.7) and regulate IRF6 expression ([@bb0075]), other experiments suggested that the IRF6 binds to upstream of *TFAP2C*, but not *TFAP2A* ([@bb0020]). A recent dual-fluorescence transgenic analysis of MCS-9.7, unambiguously demonstrated the in vivo effect of rs642961 SNP on enhancer activity ([@bb0015]). Although the *TFAP2A* is involved in orofacial development in mice, very few studies have investigated the role of *TFAP2A* in the pathogenesis NSCL/P. There is a definite need for more studies to confirm the role of *TFAP2A* variants in the causation of NSCL/P.

The following are the supplementary data related to this article.Table S1Results of association test with *TFAP2A* gene polymorphisms in sub-phenotypic groups of NSCL/P.Table S1Fig. S1Genotype and allele frequency distribution of the *TFAP2A* polymorphisms with respect to cleft phenotypes.A: genotype frequencies and B: Allele frequencies.Fig. S1
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###### 

Results of association tests with *TFAP2A* gene polymorphisms in NSCL/P and control groups.

Table 1

  SNP         Genotype     Control n (%)   Clefts n (%)        OR (95%CI)   p value
  ----------- ------------ --------------- ------------------- ------------ ----------------------------------------
  rs1675414   GG           56 (31.8)       46 (26.6)           Reference    0.297[⁎](#tf0005){ref-type="table-fn"}
  GA          83 (47.2)    96 (55.5)       1.41 (0.86--2.29)                
  AA          37 (21.0)    31 (17.9)       1.02 (0.55--1.88)                
  GA + AA     120 (68.2)   127 (73.3)      1.29 (0.81--2.04)   0.282        
  G           195 (55.4)   188 (54.3)                                       
  A           157 (44.6)   158 (45.7)      1.04 (0.77--1.40)   0.77         
  rs3798691   GG           168 (95.5)      167 (96.5)          Reference    0.608[⁎](#tf0005){ref-type="table-fn"}
  GC          8 (4.5)      6 (3.5)         0.75 (0.26--2.22)                
  CC          0 (0)        0 (0)           −                                
  GC + CC     8 (4.5)      6 (3.5)         0.75 (0.26--2.22)   0.608        
  G           344 (97.7)   340 (98.3)                                       
  C           8 (2.3)      6 (1.7)         0.76 (0.26--2.21)   0.611        
  rs303050    TT           155 (88.1)      147 (85.0)          Reference    0.194[⁎](#tf0005){ref-type="table-fn"}
  TC          19 (10.8)    26 (15.0)       1.44 (0.77--2.72)                
  CC          2 (1.1)      0 (0)           −                                
  TC + CC     21 (11.9)    26 (15.0)       0.85 (0.46--1.58)   0.61         
  T           329 (93.5)   268 (92.5)                                       
  C           23 (6.5)     26 (7.5)        1.38 (0.77--2.49)   0.269        

p value by ᵡ^2^ test (*df* = 2), p value by ᵡ^2^ test (*df* = 1).

###### 

Interaction models by MDR analysis.

Table 2

  Factors                          CVC     TA      p value
  -------------------------------- ------- ------- ---------
  rs1675414                        10/10   0.542   0.119
  rs1675414, rs303050              10/10   0.528   0.091
  rs1675414, rs3798691, rs303050   10/10   0.528   0.075

CVC: Cross validation consistency; TA: Testing accuracy.
